Granules India Ltd
GRANULESGranules India Ltd
GRANULESPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
27.02 | 4.08 | 0.28% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast from 8 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Granules India Limited is a pharmaceutical company that manufactures finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).
Investor Presentation
View olderÂPeers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,362.41 | 1,445.21 | 1,711.45 | 2,354.63 | 2,688.44 | 3,264.42 | 3,782.53 | 4,525.70 | 4,510.77 | 4,485.69 | ||||||||||
Raw Materials | 761.96 | 679.96 | 902.90 | 1,338.97 | 1,314.92 | 1,590.28 | 2,036.42 | 2,352.65 | 2,208.22 | 3,509.08 | ||||||||||
Power & Fuel Cost | 34.97 | 38.67 | 48.22 | 57.68 | 59.74 | 68.85 | 74.66 | 95.69 | 100.64 | |||||||||||
Employee Cost | 117.57 | 140.19 | 165.21 | 209.82 | 259.04 | 324.29 | 366.44 | 420.35 | 550.24 | |||||||||||
Selling & Administrative Expenses | 145.21 | 174.70 | 216.04 | 262.58 | 313.30 | 427.22 | 521.25 | 580.83 | 696.63 | |||||||||||
Operating & Other expenses | 21.20 | 78.21 | 73.83 | 26.11 | 126.33 | -28.32 | 43.92 | 148.57 | 94.66 | |||||||||||
EBITDA | 281.50 | 333.48 | 305.25 | 459.47 | 615.11 | 882.10 | 739.84 | 927.61 | 860.38 | 976.61 | ||||||||||
Depreciation/Amortization | 58.40 | 71.51 | 76.20 | 105.48 | 136.95 | 151.46 | 158.63 | 184.49 | 207.33 | 210.96 | ||||||||||
PBIT | 223.10 | 261.97 | 229.05 | 353.99 | 478.16 | 730.64 | 581.21 | 743.12 | 653.05 | 765.65 | ||||||||||
Interest & Other Items | 37.07 | 32.26 | 33.06 | 28.46 | 27.02 | 26.28 | 23.21 | 55.93 | 105.82 | 110.10 | ||||||||||
PBT | 186.03 | 229.71 | 195.99 | 325.53 | 451.14 | 704.36 | 558.00 | 687.19 | 547.23 | 655.55 | ||||||||||
Taxes & Other Items | 63.03 | 65.20 | 63.40 | 89.11 | 115.73 | 154.90 | 145.25 | 170.58 | 141.92 | 168.39 | ||||||||||
Net Income | 123.00 | 164.51 | 132.59 | 236.42 | 335.41 | 549.46 | 412.75 | 516.61 | 405.31 | 487.16 | ||||||||||
EPS | 5.84 | 7.39 | 5.50 | 9.31 | 13.19 | 21.89 | 16.65 | 21.08 | 16.73 | 20.10 | ||||||||||
DPS | 0.65 | 0.90 | 1.00 | 1.00 | 1.00 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | ||||||||||
Payout ratio | 0.11 | 0.12 | 0.18 | 0.11 | 0.08 | 0.07 | 0.09 | 0.07 | 0.09 | 0.07 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Granules India Ltd | 32.47 | 4.08 | 0.28% |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare GRANULES with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 3.09%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.31%
Top 5 Mutual Funds holding Granules India Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1020% | Percentage of the fund’s portfolio invested in the stock 2.26% | Change in the portfolio weight of the stock over the last 3 months -0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/92 (0) |
Edelweiss Balanced Advantage Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0819% | Percentage of the fund’s portfolio invested in the stock 1.16% | Change in the portfolio weight of the stock over the last 3 months 1.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 81/151 (+22) |
Axis India Manufacturing Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6886% | Percentage of the fund’s portfolio invested in the stock 1.50% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 49/93 (+3) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Granules India Ltd
Events
Dividend Trend
No Dividend Cuts
GRANULES has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.28%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.76 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 30, 2024
Dividend/Share
₹1.50
Ex DateEx Date
Jul 30, 2024
Cash Dividend
Ex DateEx DateAug 3, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Aug 3, 2023
Cash Dividend
Ex DateEx DateJul 19, 2022
Dividend/Share
₹0.75
Ex DateEx Date
Jul 19, 2022
Cash Dividend
Ex DateEx DateFeb 17, 2022
Dividend/Share
₹0.25
Ex DateEx Date
Feb 17, 2022
Cash Dividend
Ex DateEx DateNov 24, 2021
Dividend/Share
₹0.25
Ex DateEx Date
Nov 24, 2021
The United States Food and Drug Administration (USFDA) has further classified the inspection as 'Official Action Indicated' (OAI). The drug maker has responded to all the observations issued by the USFDA. Additionally, it has voluntarily undertaken a comprehensive evaluation of the facility for further enhancements that lead to improvement of the facility. 'The company will work with the US FDA on this activity and is confident that it will result in the US FDA approving the company's facility at Gagillapur in compliance with its expectations within a short time,' Granules stated in a regulatory filing. Granules India is primarily involved in the manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Granules India consolidated net profit fell 4.79% to Rs 97.23 crore on 18.74% decline in total revenue from operations to Rs 966.62 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live
C.E. Info Systems Ltd, Zen Technologies Ltd, Deepak Nitrite Ltd and Avalon Technologies Ltd are among the other losers in the BSE's 'A' group today, 03 December 2024.Granules India Ltd tumbled 9.44% to Rs 538.5 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 2.31 lakh shares were traded on the counter so far as against the average daily volumes of 83078 shares in the past one month.C.E. Info Systems Ltd crashed 8.22% to Rs 1550.5. The stock was the second biggest loser in 'A' group.On the BSE, 58968 shares were traded on the counter so far as against the average daily volumes of 8389 shares in the past one month.Zen Technologies Ltd lost 5.17% to Rs 1813.3. The stock was the third biggest loser in 'A' group.On the BSE, 27.18 lakh shares were traded on the counter so far as against the average daily volumes of 30586 shares in the past one month.Deepak Nitrite Ltd plummeted 5.05% to Rs 2617.75. The stock was the fourth biggest loser in 'A' group.On the BSE, 23267 shares were traded on the counter so far as against the average daily volumes of 28729 shares in the past one month.Avalon Technologies Ltd fell 4.67% to Rs 912. The stock was the fifth biggest loser in 'A' group.On the BSE, 32407 shares were traded on the counter so far as against the average daily volumes of 99736 shares in the past one month.Powered by Capital Market - Live
Granules India Ltd gained for a third straight session today. The stock is quoting at Rs 591.25, up 1.19% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Granules India Ltd has gained around 7.51% in last one month. Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has gained around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 9.38 lakh shares today, compared to the daily average of 26.4 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 595.1, up 1.48% on the day. Granules India Ltd is up 51.02% in last one year as compared to a 16.91% jump in NIFTY and a 38.53% jump in the Nifty Pharma index.The PE of the stock is 37.91 based on TTM earnings ending September 24.Powered by Capital Market - Live
Granules India has received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals. These targets, aligned with the 1.5'C pathway, set Granules apart as one of the select Indian pharmaceutical companies with SBTi-validated targets under the initiative's new guidelines. Granules' goals are notable for their comprehensive scope and ambition. Granules India has committed to achieving net-zero greenhouse gas (GHG) emissions across its value chain, including all subsidiaries, by FY2050. In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030, using FY2023 as the baseline, alongside transitioning to 100% renewable electricity. These near-term and long-term targets are aligned with the 1.5'C pathway, emphasizing Granules' dedication to ambitious climate action and achieving net-zero well before FY2050. Powered by Capital Market - Live
This US drug regulator conducted an inspection from 8 April to 12 April 2024. Now, the inspection is classified as 'No Action Indicated' (NAI), indicating compliance with current Good Manufacturing Practices (cGMP) standards and confirming that no further regulatory action is required. 'This outcome reflects the facility's high standards in the production of Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for both oncology and non-oncology therapeutic areas,' said the drug regulator. During the inspection, the FDA conducted a comprehensive pre-approval inspection (PAI) and cGMP audit, which concluded with zero Form 483 observations. Krishna Prasad Chigurupati, chairman & managing director of Granules India said, The successful completion of this US FDA inspection with zero observations and the subsequent receipt of the EIR with NAI status reflects our unwavering commitment to maintaining the highest quality standards in our manufacturing operations. Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). Granules India consolidated net profit fell 4.79% to Rs 97.23 crore on 18.74% declined in total revenue from operations to Rs 966.62 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live
Net profit of Granules India declined 4.79% to Rs 97.23 crore in the quarter ended September 2024 as against Rs 102.12 crore during the previous quarter ended September 2023. Sales declined 19.48% to Rs 956.52 crore in the quarter ended September 2024 as against Rs 1188.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales956.521188.00 -19 OPM %21.2617.93 - PBDT180.91188.54 -4 PBT128.38136.02 -6 NP97.23102.12 -5 Powered by Capital Market - Live
Bupropion hydrochloride extended-release tablets USP (SR) is bioequivalent and therapeutically equivalent to wellbutrin SR sustained-release tablets, 100 mg, 150 mg, and 200 mg, by GlaxoSmithKline LLC. The approved ANDA is a widely prescribed medication for the treatment of major depressive disorder and for the prevention of seasonal affective disorder. The group now has a total of 67 ANDA approvals from the US FDA. Dr. Krishna Prasad Chigurupati, chairman and managing director, Granules India, said, This ANDA approval marks a significant milestone in our journey to expand Granules' presence in the U.S. market. Our continued focus on expanding our product portfolio in regulated markets like the U.S. ensures that we are meeting the growing healthcare needs of patients globally, while maintaining the highest standards of safety and efficacy.' Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company reported a consolidated net profit of Rs 134.65 crore in Q1 FY25, steeply higher than Rs 47.89 crore posted in Q1 FY24. Revenue from operations in first quarter of FY25 was at Rs 1,179.87 crore, up 19.72% from Rs 985.52 crore reported in the same period a year ago. Shares of Granules India shed 0.19% to Rs 592.15 on the BSE.Powered by Capital Market - Live
Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) 100 mg, 150 mg, and 200 mg filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company. Bupropion Hydrochloride Extended-Release Tablets USP (SR) are bioequivalent and therapeutically equivalent to Wellbutrin SR Sustained-Release Tablets, 100 mg, 150 mg, and 200 mg, by GlaxoSmithKline LLC. This is a widely prescribed medication for the treatment of major depressive disorder and for the prevention of seasonal affective disorder. Granules now has a total of 67 ANDA approvals from the US FDA.Powered by Capital Market - Live
Granules India will hold a meeting of the Board of Directors of the Company on 6 November 2024.Powered by Capital Market - Live
Granules India Ltd is up for a fifth straight session today. The stock is quoting at Rs 605.5, up 0.27% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.69% on the day, quoting at 25137.7. The Sensex is at 82005.67, up 0.77%. Granules India Ltd has gained around 10.11% in last one month. Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has gained around 0.37% in last one month and is currently quoting at 23582.25, down 0.2% on the day. The volume in the stock stood at 25.12 lakh shares today, compared to the daily average of 46.32 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 608.35, up 0.5% on the day. Granules India Ltd is up 71.77% in last one year as compared to a 27.4% jump in NIFTY and a 55.19% jump in the Nifty Pharma index.The PE of the stock is 32.51 based on TTM earnings ending June 24.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.88%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 1.07% to 1.2%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.38%, vs industry avg of 15.27%